When the Best Testosterone Treatment Isn't Testosterone

For decades, the logic seemed obvious: low testosterone in obese men means they need testosterone. Give the hormone, fix the problem. But a convergence of evidence from 2024-2026 is dismantling this assumption — and suggesting that for millions of men, the most effective testosterone treatment may be a drug that never touches a testosterone receptor.

This article traces three lines of evidence that, together, are reshaping how we understand the relationship between obesity and low testosterone in men. The conclusion isn't intuitive, but the data are hard to argue with.

The Scale of the Problem

Obesity is the single largest risk factor for low testosterone in men. A meta-analysis of 45 studies found functional hypogonadism in 64% of men with morbid obesity. The relationship is dose-dependent: the more excess weight, the lower the testosterone. And it runs both directions — low testosterone promotes fat accumulation, insulin resistance, and further weight gain, creating a self-reinforcing spiral.

This isn't just about sexual function. These men face increased cardiovascular risk, metabolic syndrome, depression, fatigue, and reduced quality of life. The default clinical response has been testosterone replacement therapy (TRT) — and for men with genuinely pathological hypogonadism, that remains appropriate. But for the majority, the story turns out to be more complicated.

Provocation One: Is It Even Hypogonadism?

In September 2025, Muir, Wittert, and Handelsman published a provocative reframing in The Journal of Clinical Endocrinology & Metabolism. Their argument: most obese men with "low testosterone" aren't actually hypogonadal. They coined the term "pseudo-hypogonadism of obesity."

Their reasoning is elegant. In obesity:

• Hyperinsulinemia, hepatic steatosis, and hypertriglyceridemia all suppress SHBG production
• Lower SHBG means lower measured total testosterone — but free testosterone (the biologically active form) may be adequate
• LH and FSH — the pituitary hormones that drive testicular function — remain normal

"LH and FSH operate as highly sensitive tissue androgen sensors," Muir wrote. If the pituitary isn't alarmed — if it's not sending distress signals to the testes — then the body's androgen status may be adequate despite the low number on the lab report.

Their conclusion: this is a proportionate, adaptive reduction in testosterone — not a disease state. And it reverses with weight loss.

Where Muir Goes Too Far

The SHBG mechanism is well-established and the logic is sound. But the "pseudo-hypogonadism" framing is too binary. It doesn't engage with three well-documented mechanisms of genuine central HPG suppression in obesity:

1. Leptin resistance. In severe obesity, hypothalamic neurons become resistant to leptin signaling. Leptin normally stimulates kisspeptin neurons, which drive GnRH pulsatility. Leptin resistance → kisspeptin downregulation → reduced GnRH pulse frequency → genuine central hypogonadism.
2. Inflammatory GnRH suppression. Visceral adiposity produces TNF-alpha, IL-6, and other pro-inflammatory cytokines that directly inhibit hypothalamic GnRH release. This is not an SHBG artifact — it's a real signal disruption.
3. Estrogen excess. Aromatase in adipose tissue converts testosterone to estradiol. Elevated E2 feeds back to the hypothalamus and pituitary, suppressing GnRH and LH secretion. This creates genuine central suppression, not just a measurement artifact.

The truth is a spectrum. At one end: mild obesity with proportionate SHBG reduction, normal gonadotropins, and adequate free testosterone. At the other: severe obesity with leptin resistance, inflammatory GnRH suppression, genuinely low LH, and real central hypogonadism. Most men fall somewhere between these poles. Calling it all "pseudo" understates the biology.

But Muir's core insight remains valid: a low total testosterone number, by itself, is not a diagnosis. LH, FSH, SHBG, and free testosterone must be interpreted together — and the degree of obesity must be considered as context, not ignored.

Provocation Two: The Leflutrozole Paradox

If the pseudo-hypogonadism thesis is one crack in the "just give testosterone" assumption, leflutrozole is another.

Leflutrozole is a novel once-weekly aromatase inhibitor (AI) developed by Mereo BioPharma. In a Phase 2b trial across 70 sites, it was tested in men with BMI 30-50 and total testosterone below 10.41 nmol/L (300 ng/dL). The mechanism is logical: block aromatase → less testosterone converts to estradiol → less negative E2 feedback → LH rises → testes produce more testosterone.

And it worked — pharmacologically. Leflutrozole produced dose-dependent testosterone normalization, reaching mean levels of 20.35 nmol/L (587 ng/dL) versus 8.04 nmol/L (232 ng/dL) with placebo.

But here is the paradox: normalized testosterone produced no improvement in sexual dysfunction and no change in body composition.

The trial also raised safety concerns: bone density decreased by 2.09%, hematocrit rose, and PSA increased — the predictable costs of aggressive aromatase inhibition without the expected clinical benefit.

This finding is profound. If you pharmacologically normalize testosterone in obese hypogonadal men and their symptoms don't improve, then low testosterone was a marker of the metabolic dysfunction, not the primary driver of the symptoms. The number changed. The disease didn't.

This doesn't mean testosterone is irrelevant in obesity. It means that addressing only the hormone — while leaving the obesity, insulin resistance, inflammation, and metabolic dysfunction untouched — misses the point.

Provocation Three: The GLP-1 RA Revolution

Then came the tirzepatide data, and the picture snapped into focus.

Tirzepatide is a dual GIP/GLP-1 receptor agonist — a weight loss and diabetes drug. It was not designed to treat hypogonadism. But at ENDO 2025, Cannarella and colleagues presented results from a controlled pilot study of 83 obese men with metabolic hypogonadism that stopped the field in its tracks.

Three groups: tirzepatide (2.5→5mg weekly, n=28), lifestyle changes only (n=30), or transdermal TRT (n=25). All followed a hypocaloric diet with daily walking. Duration: 2 months.

The headline finding: hypogonadism was reversed in 100% of patients treated with tirzepatide. Not with testosterone. With a weight loss drug.

But look at the details, because they matter:

• Total testosterone more than doubled (186 → 424 ng/dL) — far exceeding TRT's effect (186 → 272) and lifestyle alone (192 → 266).
• LH increased by 73% (2.6 → 4.5 mIU/mL). This is the key distinction from TRT. TRT delivers exogenous testosterone, which feeds back to suppress LH — the pituitary stops signaling the testes. Tirzepatide did the opposite: it restored the brain's signal to the testes. The HPG axis woke up.
• Estradiol plummeted 67% (33 → 11 pg/mL). With less fat, there was less aromatase activity, less T→E2 conversion, less estrogenic feedback suppressing GnRH. The axis unburdened itself.
• Lean mass increased 17.9%. This addresses the elephant in the GLP-1 RA room — the concern that these drugs cause muscle loss. In the general population, they do: the STEP-1 substudy showed ~3 kg lean mass reduction with semaglutide. But in hypogonadal men, the testosterone restoration that accompanied weight loss actually promoted muscle protein synthesis. The lean mass concern applies to eugonadal patients, not these men.

"The presence of hypogonadism was reversed in all patients that were treated with tirzepatide, which was really a remarkable finding," Cannarella told the Endocrine Society.

Beyond the Cannarella Pilot

Cannarella's study was small (n=28 on tirzepatide), non-randomized, and only 2 months long. But it isn't an island. Multiple systematic reviews and meta-analyses from 2025-2026 tell the same story:

• A 2026 meta-analysis of GLP-1 RAs found a significant increase in total testosterone with a standardized mean difference of 1.39 ng/mL (95% CI: 0.70-2.09, p < 0.0001), with corresponding increases in SHBG, LH, and FSH.
• A real-world study of 110 patients on semaglutide, dulaglutide, or tirzepatide for 18 months found that 10% weight loss produced a 53-77% testosterone increase.
• After bariatric surgery, which produces greater and more sustained weight loss, as many as 87% of previously hypogonadal men normalize testosterone levels.
• A January 2026 systematic review in the Journal of Sexual Medicine found that GLP-1 RAs not only improve testosterone but may also enhance semen quality — serving as fertility-sparing alternatives to TRT.

One retrospective chart review found something particularly striking: no significant relationship between weight change and testosterone change (p=0.969) in GLP-1 RA-treated patients. The testosterone increase appeared to be at least partially independent of weight loss itself.

A Direct Testicular Effect?

This brings us to one of the more intriguing findings in recent years. Caltabiano and colleagues demonstrated in 2020 that GLP-1 receptors are expressed in human Leydig cells — the testicular cells that produce testosterone. They confirmed this at multiple levels: immunohistochemistry, RNA in situ hybridization, Western blot, and PCR.

In vitro, the GLP-1 receptor agonist Exendin-4 at 300 pM induced a significant increase in testosterone secretion from mouse Leydig cells. And GLP-1 null male mice are completely infertile with abnormal gonadal development.

This suggests GLP-1 RAs may not be acting solely through weight loss and insulin sensitization. They may have direct effects on testicular function — stimulating Leydig cells via the same receptor they activate in pancreatic beta cells. The signaling pathway appears similar: cAMP and protein kinase A (PKA) activation.

Caution is warranted. These are mostly in vitro and animal data. But combined with the clinical observation that testosterone increases seem disproportionate to weight loss, the hypothesis of a direct testicular mechanism is gaining ground.

Why This Changes the Treatment Algorithm

Put the three provocations together and a new framework emerges:

1. TRT replaces the end product but suppresses the axis, impairs fertility, and leaves the obesity untreated. Estradiol often rises (more testosterone substrate for aromatase). The underlying disease marches on.
2. Aromatase inhibitors normalize the number but don't fix the symptoms — because the number wasn't the problem. Safety concerns pile up.
3. GLP-1 receptor agonists treat the root cause. Weight loss reverses the SHBG depression, reduces aromatase activity, resolves leptin resistance, quiets inflammation, and allows the HPG axis to restore itself. Testosterone rises because the testes start receiving the signals they need. Fertility is preserved. And there may be direct testicular benefits on top.

This doesn't mean TRT has no role. For men with severe symptoms and genuinely pathological hypogonadism (organic pituitary disease, Klinefelter syndrome, prior cancer therapy), TRT remains essential. An FDA expert panel in December 2025 recommended expanded TRT access following reassuring cardiovascular safety data from the TRAVERSE trial — and for the right patients, that's appropriate.

But for the largest population of hypogonadal men — those whose low testosterone is driven primarily by metabolic dysfunction — the evidence increasingly says: treat the metabolism first.

Sleep: The Overlooked Third Pillar

Weight loss isn't the only root-cause intervention gaining evidence. A 2025 paper in Medical Hypotheses proposed that much of what we call "age-related testosterone decline" is actually sleep-disruption-induced hypogonadism — driven by accumulating sleep-fragmenting conditions (BPH causing nocturia, obstructive sleep apnea, chronic pain) rather than aging per se.

This isn't just theoretical. Amodeo and colleagues published in the Journal of Clinical Endocrinology & Metabolism (November 2025) a study of 204 severely obese men showing that decompensated obstructive sleep apnea (OSA) was an independent contributor to low testosterone — not just a proxy for obesity. More importantly: CPAP treatment improved testosterone levels independently of BMI changes after 3 months.

This dovetails with older data showing that just one week of sleep restriction drops testosterone 10-15% in healthy young men. The HPG axis is exquisitely sensitive to sleep architecture. GnRH pulses are tightly coupled to sleep stages.

For obese hypogonadal men with untreated sleep apnea, the emerging prescription is clear: treat the breathing, treat the weight, and watch the testosterone take care of itself.

What About the Lean Mass Concern?

The biggest clinical objection to GLP-1 RAs is muscle loss. The STEP-1 substudy with semaglutide showed lean mass loss of roughly 3 kg. The SURMOUNT-1 trial with tirzepatide showed similar patterns. Won't losing muscle mass worsen functional outcomes, especially in older men?

Three counterpoints:

1. In hypogonadal men specifically, the concern may not apply. Cannarella's data showed +17.9% lean mass gain in the tirzepatide group — because testosterone restoration promotes muscle protein synthesis. The lean mass concern is real for eugonadal patients; in hypogonadal men, T restoration may be protective.
2. "Lean mass" is not synonymous with "muscle mass." A 2025 Circulation review pointed out that much of the lean mass lost during GLP-1 RA therapy is water, organ downsizing, intramuscular fat reduction, and other adaptive changes — not contractile muscle tissue.
3. Resistance exercise mitigates the issue. The LEAN-PREP trial (NCT06885736, starting March 2026) is specifically studying whether resistance training and protein supplementation preserve lean mass during semaglutide/tirzepatide therapy.

The Limits of the Evidence

Intellectual honesty demands acknowledging what we don't yet know:

• No RCT with hypogonadism as primary endpoint. As of early 2026, no published randomized controlled trial has studied GLP-1 RAs with hypogonadism reversal as the primary outcome. The Cannarella study was controlled but not randomized, and lasted only 2 months. The longer-term durability of HPG axis restoration is unknown.
• Semaglutide vs. tirzepatide. Most hormonal data come from mixed GLP-1 RA studies. Whether tirzepatide's dual GIP/GLP-1 mechanism offers advantages over pure GLP-1 RAs for testosterone specifically is untested.
• Direct testicular effects remain unproven in humans. GLP-1 receptors in Leydig cells are confirmed, and in vitro stimulation increases testosterone secretion. But we don't know whether clinically achievable GLP-1 RA concentrations produce meaningful direct testicular effects in vivo.
• The spectrum problem. We lack reliable clinical tools to distinguish men with pure SHBG-driven pseudo-hypogonadism from those with genuine central HPG suppression. LH and free testosterone help, but the cutoffs are imprecise.
• Cost and access. GLP-1 RAs are expensive ($800-1300/month in the US), often poorly covered by insurance for obesity alone, and subject to ongoing shortages. TRT, by comparison, is cheap and widely available.

These gaps matter. But they don't change the direction of the evidence — they just define how far we can push the conclusions today.

What This Means

The emerging framework for obesity-associated hypogonadism looks like this:

1. Diagnose correctly. A low total testosterone in an obese man is not automatically hypogonadism. Check LH, FSH, SHBG, free/bioavailable testosterone, prolactin, and TSH. Screen for sleep apnea. Interpret the numbers in context.
2. Treat the root cause first. Weight loss — through lifestyle, GLP-1 RAs, or bariatric surgery — should be the foundation. Treat sleep apnea if present. These interventions address the disease, not just the number.
3. Reserve TRT for genuine pathology. Men with organic pituitary disease, severe symptoms (T < 200 ng/dL), or inadequate response to root-cause treatment may need testosterone replacement. That's appropriate. What's not appropriate is defaulting every obese man with a low T to lifelong exogenous hormone therapy that suppresses his axis and leaves his obesity untreated.
4. Preserve fertility. For men who want children, GLP-1 RAs preserve gonadotropin function and may even improve semen parameters. TRT does the opposite — suppressing spermatogenesis, often to azoospermia. This distinction alone should reshape prescribing decisions.
5. Follow the patient, not the number. The leflutrozole paradox taught us that normalizing testosterone doesn't necessarily fix symptoms. The goal is metabolic health, functional recovery, and quality of life — not a lab value.

The best testosterone treatment for most obese hypogonadal men isn't testosterone. It's treating what made their testosterone low in the first place.

---

Sources

• Muir CA, Wittert GA, Handelsman DJ. "Pseudo-hypogonadism of obesity." J Clin Endocrinol Metab. Sept 2025.
• Cannarella R, et al. "Short-term impact of tirzepatide on metabolic hypogonadism and body composition in patients with obesity." Reprod Biol Endocrinol. July 2025. PMID: 40604795.
• Mereo BioPharma. Leflutrozole Phase 2b results. Eur J Endocrinol. Sept 2023.
• Caltabiano R, et al. "Glucagon-like peptide-1 receptor is expressed in human and rodent testis." Andrology. 2020. PMID: 33460247.
• Salvio G, et al. "Effects of GLP-1 RAs on testicular dysfunction: A systematic review and meta-analysis." Andrology. 2025.
• Meta-analysis: "Effect of GLP-1 agonists on testosterone levels." PMC. 2026. PMC12752444.
• Amodeo C, et al. "OSA and testosterone in severe obesity." J Clin Endocrinol Metab. Nov 2025.
• Sleep-disruption-induced hypogonadism hypothesis. Med Hypotheses. 2025.
• "Lean mass" clarification. Circulation. 2025 review.
• FDA Advisory Panel on TRT access expansion. Dec 2025.
• TRAVERSE trial cardiovascular safety data. N Engl J Med. 2023.